ClinConnect ClinConnect Logo
Search / Trial NCT05780034

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Launched by ACCUTAR BIOTECHNOLOGY INC · Mar 10, 2023

Trial Information

Current as of July 21, 2025

Recruiting

Keywords

Chronic Lymphocytic Leukemia (Cll) Small Lymphocytic Lymphoma (Sll) Mantle Cell Lymphoma (Mcl) Follicular Lymphoma (Fl) Non Germinal Center B Cell (Non Gcb) Diffuse Large B Cell Lymphoma (Dlbcl) Marginal Zone Lymphoma (Mzl Waldenström Macroglobulinemia (Wm) Non Hodgkin Lymphoma (Nhl) Bruton's Tyrosine Kinase Btk Btk Degrader Ac676 Ac0676

ClinConnect Summary

This clinical trial is studying a new drug called AC676 to see how well it works for patients with certain types of blood cancers, specifically those who have not responded to previous treatments. The main goals are to find out the safest dose of AC676, understand its safety and how the body processes it, and see how effective it is in treating these cancers. The trial is currently looking for adult participants aged 18 and older who have been diagnosed with specific types of relapsed or refractory B-cell malignancies and have already received at least two prior treatments.

If you join this study, you will be monitored closely for any side effects and how well the drug is working. It’s important to note that there are some requirements to participate, such as not having received certain treatments recently or having specific medical conditions. This study aims to provide more options for patients with limited treatment choices, helping to improve care for those fighting these challenging diseases.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Adult male and female patients, at least 18 years-of-age at the time of signature of the informed consent form (ICF).
  • 2. Patients with histologically confirmed relapsed/refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM).
  • 3. Must have received at least 2 prior systemic therapies or have no other therapies to provide significant clinical benefit in the opinion of the Investigator or who are not amenable (intolerability, patient choice) to standard therapies.
  • Exclusion Criteria:
  • Patients who meet any of the following criteria will be excluded from study entry:
  • 1. Treatment with any of the following:
  • Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days).
  • Systemic chemotherapy within 14 days.
  • Radiation therapy within 14 days
  • Biologics (Antibodies) treatment within 28 days,
  • Radioimmunoconjugates or toxin conjugates within 12 weeks.
  • Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed.
  • Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD.
  • 2. History of central nervous system lymphoma/leukemia in remission for less than 2 years.
  • 3. Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator.

About Accutar Biotechnology Inc

Accutar Biotechnology Inc. is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for the treatment of serious diseases. With a strong focus on precision medicine, Accutar leverages cutting-edge technologies and a robust pipeline of drug candidates to address unmet medical needs in oncology and other critical therapeutic areas. The company emphasizes a collaborative approach, partnering with leading research institutions and industry experts to accelerate the development of transformative treatments. Committed to scientific excellence and patient-centric solutions, Accutar Biotechnology Inc. strives to enhance the quality of life for patients worldwide through its groundbreaking research and development initiatives.

Locations

Seattle, Washington, United States

Dallas, Texas, United States

Portland, Oregon, United States

Denver, Colorado, United States

Sarasota, Florida, United States

Nashville, Tennessee, United States

Columbus, Ohio, United States

Nashville, Tennessee, United States

Sarasota, Florida, United States

Denver, Colorado, United States

Nashville, Tennessee, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials